再生医学公司和3D BioProinter材料开发人员填料(NASDAQ:CLGN) , has reported its financial results for the third quarter of 2018. Headline revenue for the three months ended September 30, 2018 was $224,000, a 209% increase on the same period in 2017, which was $73,000. The increase is reflective of the growing commercialization of the company’s proprietary materials.
In a press release on the financial report Yehiel Tal, CollPlant CEO, commented, “During the third quarter we made progress advancing our other 3D bioprinting business. We are moving forward with our development activities with various companies that are using CollPlant’s rhCollagen based BioInk for the bioprinting of organs and tissues.”
从烟草植物中提取的生物材料
目前，纸型在市场上有三种材料：
– VergenixSTR, a soft tissue repair gel designed to form a metric for Platelet Rich Plasma (PRP), and treat chronic tendon and ligament disorders.
– VergenixFG, a collagen gel for addition to bandages and improving wound care.
– And itRhcollagenbioink, its primary solution for 3D bioprinting with live cell content for which it has a separate development division.
Rhcollagen Bioink是从烟草植物生物工程生物生物生产并收获的，从而产生了活胶原蛋白。Rhcollagen也将用于新形成的肺部生物打印项目Collplant和United Therapeutics Corporation。作为联合治疗公司的子公司Lung Biotechnology PBCthat is working on this project with CollPlant, also has a与3D系统达成的3D生物打印协议。
由美国胶原蛋白销售驱动
根据2018财年第三季度的报告，本季度的收入主要由欧洲Collgenixstr材料的欧洲销售和美国的Rhcollagen销售主导。
Operating expenses in Q3 FY2018 have risen in comparison to last year, from $1.1 million to $1.7 million. This rise has been primarily attributed to an increase in salaries and share expenses. Of the $1.7 million operating cost for Q3 2018, general, administrative and marketing costs equate to $748 thousand. The company has also spent more on research and development in this quarter than in Q3 2017. Net research and development expenses for Q3 2018 were reported at $941 thousand, compared to $740 thousand for the same period in 2017.
这填料Third Quarter 2018 Financial Results报告，包括2018年前九个月的结果，可以在此处在线找到。
In closing comment on the report, Tal stated, “Based on our work with major market players in the fields of 3D bioprinting and medical aesthetics, we believe that CollPlant’s rhCollagen is the ideal building block for regenerative medicine scaffolds available today, and will play a critical role in those markets.”
特色图片节目ODED Shoseyov教授，Colleplant Holdings Ltd.的创始人。
